IPO Timeline
Broker Results (T-2)
2021-02-24
Some brokers release in afternoon
Grey Market (T-1)
2021-02-25
Afternoon
HKEX Allotment (T-1)
2021-02-25
Evening
Registrar Allotment (T-1)
2021-02-25
Evening
Listing Day (T)
2021-02-26
First day of trading
Cross-Market Price Comparison
| Other Listed Market | Shanghai (SSE) — 昭衍新药 |
|---|---|
| Other Market Stock Code | 603127 |
| H-Share Offer Price | To be extracted |
| Other Market Price | Loading... |
| Reference Exchange Rate | Loading... |
| H-Share Offer Price Premium/Discount vs Other Market | Loading... |
Company Overview
| Stock Name | 北京昭衍新藥研究中心股份有限公司 |
|---|---|
| Stock Code | 06127 |
| Company Full Name | 北京昭衍新藥研究中心股份有限公司 |
| Industry | 醫療保健 |
| Principal Activities | 主要提供非臨床研究服務及臨床試驗及相關服務，亦銷售實驗模型。 |
| Listing Date | 2021-02-26 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國北京市北京經濟技術開發區榮京東街甲5號 |
| Business Address (Hong Kong) | To be extracted |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | http://www.joinn-lab.com |
| Share Registrar | 卓佳证券登记有限公司 (Tricor Investor Services Limited) |
| Registrar Contact | (852)2980 1333 |
| A-Share/US Dual Listing | No data |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 151.00 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | To be extracted |
| Global Offering Shares | To be extracted |
| HK Public Offer Shares (Initial) | To be extracted |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | To be extracted |
| Offer Ratio | To be extracted |
| Total Shares Post-IPO | To be extracted |
| Greenshoe (Over-allotment Option) | To be confirmed |
| Stabilizing Manager (Greenshoe) | — |
| Cornerstone Share | 31.8% |
| Clawback Tiers | To be extracted |
| Reallocation Option | To be confirmed |
| Total Global Offering Size | HK$ 2,355,147,000 |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | To be extracted |
| P/E Ratio | To be extracted |
| Profit/Loss Status | To be extracted |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
First Day Performance
| First Day Close | HK$ 138.0 |
|---|---|
| First Day Open | HK$ 148.0 |
| First Day Change | -8.61% |
| First Day Volume | 11667400.0 |
| First Day Turnover | 1675200000.0 |
Use of Proceeds
| Use of Proceeds | 1、16.0%或1,005.8百萬港元將用于進一步擴大我們于蘇州的設施網絡乃為我們的未來增長提供必要的支持； 2、10.0%或628.6百萬港元將用于增強我們的美國業務以迎合客戶對Biomere所提供服務日益增長的需求； 3、39.0%或2,451.6百萬港元將用于進一步擴大我們于中國的設施網絡及服務能力； 4、5.0%或314.3百萬港元將用于拓展及深化我們的綜合合同研究組織服務； 5、20%或1,257.2百萬港元將用于進一步實施我們拓寬藥物研發價值鏈上的綜合服務范圍并拓展海外布局的策略； 6、10%或628.6百萬港元將用于營運資金及一般企業用途。 |
|---|
Underwriting Syndicate
Sole Sponsor (1)
中信证券（香港）有限公司 CE AAK249
Overall Coordinators (3)
中信里昂证券有限公司 CE AAB893
Merrill Lynch (Asia Pacific) Limited CE AAC198
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (9)
中信里昂证券有限公司 CE AAB893
Merrill Lynch (Asia Pacific) Limited CE AAC198
中国国际金融香港证券有限公司 CE AEN894
招商证券（香港）有限公司 CE AAI650
海通国际证券有限公司 CE AAF806
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
交银国际证券有限公司 CE APJ121
工银国际证券有限公司 CE ARO299
Joint Lead Managers (9)
中信里昂证券有限公司 CE AAB893
Merrill Lynch (Asia Pacific) Limited CE AAC198
中国国际金融香港证券有限公司 CE AEN894
招商证券（香港）有限公司 CE AAI650
海通国际证券有限公司 CE AAF806
中银国际亚洲有限公司 CE AET863
招银国际融资有限公司 CE AVM940
交银国际证券有限公司 CE APJ121
工银国际证券有限公司 CE ARO299
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Carmignac Funds | 155,046,800 HKD | — | 2.40% | — | 6 months | 2021-08-26 |
| 2 | CPE Greater China Enterprises Growth Fund | 271,347,000 HKD | — | 4.10% | — | 6 months | 2021-08-26 |
| 3 | CRF Investment Holdings Company Limited | 232,585,300 HKD | — | 3.60% | — | 6 months | 2021-08-26 |
| 4 | Janchor Partners Pan-Asian Master Fund | 232,585,300 HKD | — | 3.60% | — | 6 months | 2021-08-26 |
| 5 | Lake Bleu Prime Healthcare Master Fund Limited | 294,601,000 HKD | — | 4.50% | — | 6 months | 2021-08-26 |
| 6 | Octagon Capital Advisors LP | 77,523,400 HKD | — | 1.20% | — | 6 months | 2021-08-26 |
| 7 | OrbiMed Funds | 271,347,000 HKD | — | 4.10% | — | 6 months | 2021-08-26 |
| 8 | SCC Growth VI Holdco F, Ltd. | 232,585,300 HKD | — | 3.60% | — | 6 months | 2021-08-26 |
| 9 | The Valliance Fund | 38,761,700 HKD | — | 0.60% | — | 6 months | 2021-08-26 |
| 10 | 中国国有企业结构调整基金股份有限公司 | 271,347,000 HKD | — | 4.10% | — | 6 months | 2021-08-26 |
Directors & Management
| Chairman | 馮宇霞 |
|---|---|
| Company Secretary | 高大鵬;張嘉倫 |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 馮宇霞及家族成員(22.35%) |
|---|
IPO Timeline
